At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 318 enrolled
Drug / intervention
tirzepatide +2 moredrug
Likely dose
Tirzepatide administered subcutaneously once weekly (dose not specified in published criteria/arms)AI-extracted
Key inclusion· 4
- ✓Type 2 diabetes for at least 6 months
- ✓HbA1c between 7.0% and 10.5%
- ✓BMI ≥23 and <50 kg/m²
- ✓If on metformin, stable dose for at least 3 months
Key exclusion· 8
- ✕Type 1 diabetes
- ✕Prior GLP-1 receptor agonist use at any time
- ✕Other glucose-lowering medications (except metformin) within 3 months prior to entry
- ✕Recent cardiovascular events: MI, NYHA Class III–IV heart failure, or stroke
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating tirzepatide, Dulaglutide, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 318 participants across 49 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesPoland, Puerto Rico, Slovakia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedApr 27, 2017
Enrollment StartMay 24, 2017
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.2 years ago
Interventions
tirzepatidedrug
Administered SC
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC